Navigation Links
Genomma Lab Announces Its 2010 Earnings Guidance
Date:12/11/2009

MEXICO CITY, Dec. 11 /PRNewswire-FirstCall/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB) ("Genomma Lab" or "the Company") announces today its 2010 earnings guidance.

Genomma Lab expects net sales growth in the range of 42% to 45% for the full year of 2010, excluding possible acquisitions, and an EBITDA margin between 25.0% and 26.0%, from 2009 year-end results which we expect to be above our last issued guidance.

The Company's estimates are based on organic growth in base line products, the full year effect in sales of products launched or acquired during 2009, growth in international operations as well as product line extensions and new brands in existing and new categories.

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Latin America. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. The Company has a sound business model through a unique combination of a new product development process, consumer oriented marketing, a broad retail distribution network and a low-cost, highly flexible supply chain operating model.

    Contact: Oscar Villalobos
    Tel:  +52 (55) 5081- 0000 ext. 4250
    E-mail: inversion@genommalab.com

    In New York: i-advize Corporate Communications, Inc.
    Tel: (212) 406-3695
    E-mail: genomma@i-advize.com

SOURCE Genomma Lab Internacional, S.A.B. de C.V.


'/>"/>
SOURCE Genomma Lab Internacional, S.A.B. de C.V.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Strategic Alliance Between Televisa and Genomma Lab
2. Genomma Lab Internacional Revises 2009 Earnings Guidance
3. Strategic Alliance Between Televisa and Genomma Lab
4. Genomma Lab International Announces Second Quarter 2009 Results
5. Webcast Alert: Genomma Lab Internacional, S.A.B. de C.V. Announces Second Quarter 2009 Results Conference Call
6. Genomma Lab Internacional Acquires Brands Flor de Naranja Sanborns(MR), Teatrical and Henna Egipcia From Grupo Sanborns
7. Genomma Lab Internacional Announces First Quarter 2009 Results
8. Genomma Lab Acquires the Mexican Company Medicinas y Medicamentos Nacionales
9. Genomma Lab Internacional Announces Fourth Quarter and Full Year 2008 Results
10. Webcast Alert: Genomma Lab Announces Fourth Quarter 2008 Earnings Webcast
11. Genomma Lab Announces Updated Fourth Quarter 2008 Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... RICHEY, Fla. (PRWEB) , ... April 24, 2017 ... ... and Prevention (CDC), rising prescription opioid overdose deaths now claim the lives of ... slashed its civil case filings against drug manufacturers, distributors, pharmacies and prescribers by ...
(Date:4/24/2017)... ... April 24, 2017 , ... Pitavastatin, a relatively ... it is not known to have significant interactions with antiretroviral therapy (ART). ... cholesterol levels and dampen inflammation in the bloodstream. , While lowering cholesterol and ...
(Date:4/24/2017)... ... April 24, 2017 , ... Donna Parker, L. Ac. reads all sorts of ... of them to be very practical. She wanted to write a guide/workbook that would ... their health. It prompted her in writing “ A Clear Path to a Vibrant ...
(Date:4/24/2017)... ... April 24, 2017 , ... “The Saint with Trin, ... Trin, and Omega Station” is the creation of published author, Chris Jackson. Chris ... where he works in the Dallas Independent School District teaching English. He is heavily ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... of next generation neuro-thrombectomy systems for the treatment of Acute Ischemic Stroke (AIS), ... ANCD BRAIN device as the product advances towards regulatory and clinical phases. , ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... Tenn. and DALLAS , April 19, 2017 ... announced that the first patients in Nashville ... device in the Lower Esophageal Sphincter Stimulation for GERD ... implantable device designed to provide long-term reflux control by ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)... April 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... biopharmaceutical company developing new treatments for cancer and ... of its previously announced underwritten public offering of ... public offering price of $2.00 per share, before ... expenses payable by Sorrento.  The net proceeds to ...
(Date:4/19/2017)... April 19, 2017  New research provides evidence that an ... according to a study released today that will be presented ... in Boston , April 22 to ... treatment of Parkinson,s disease, the oral drug levodopa has long ... longevity. But as the disease progresses, the effects of the ...
Breaking Medicine Technology: